US9511092B2
(en)
|
2013-01-28 |
2016-12-06 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
|
CN113684185A
(en)
*
|
2013-02-26 |
2021-11-23 |
纪念斯隆-凯特琳癌症中心 |
Compositions and methods for immunotherapy
|
NZ712693A
(en)
*
|
2013-03-15 |
2021-07-30 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for immunotherapy
|
RU2668560C2
(en)
|
2013-03-29 |
2018-10-02 |
Сумитомо Дайниппон Фарма Ко., Лтд. |
Conjugate vaccine on basis of antigen wt1 peptide
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
CN106456724A
(en)
|
2013-12-20 |
2017-02-22 |
博德研究所 |
Combination therapy with neoantigen vaccine
|
US11390921B2
(en)
|
2014-04-01 |
2022-07-19 |
Adaptive Biotechnologies Corporation |
Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
|
KR20220136455A
(en)
|
2014-04-23 |
2022-10-07 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
|
CA2948462A1
(en)
|
2014-05-15 |
2015-11-19 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
CN107109419B
(en)
|
2014-07-21 |
2020-12-22 |
诺华股份有限公司 |
Treatment of cancer using CD33 chimeric antigen receptor
|
US9546206B2
(en)
|
2014-08-08 |
2017-01-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity PD-1 agents and methods of use
|
TWI805109B
(en)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
Antibodies and chimeric antigen receptors specific for cd19
|
US10577417B2
(en)
*
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
JP7057669B2
(en)
|
2014-10-20 |
2022-04-20 |
ジュノー セラピューティクス インコーポレイテッド |
Methods and Compositions for Dosing in Adoptive Cell Therapy
|
MX2017005344A
(en)
*
|
2014-10-27 |
2017-08-15 |
Hutchinson Fred Cancer Res |
Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy.
|
AU2015338984A1
(en)
*
|
2014-10-31 |
2017-04-27 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for modified T cells
|
SG11201704549UA
(en)
|
2014-12-05 |
2017-07-28 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
RS61781B1
(en)
|
2014-12-05 |
2021-06-30 |
Memorial Sloan Kettering Cancer Center |
Antibodies targeting b-cell maturation antigen and methods of use
|
CN116063565A
(en)
|
2014-12-05 |
2023-05-05 |
纪念斯隆-凯特琳癌症中心 |
Chimeric antigen receptor targeting Fc receptor-like 5 and uses thereof
|
EP3234193B1
(en)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molecular biomarkers for cancer immunotherapy
|
JP2018504894A
(en)
*
|
2014-12-19 |
2018-02-22 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Chimeric antigen receptor and method of use thereof
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
US20180021378A1
(en)
*
|
2014-12-31 |
2018-01-25 |
Anthrogenesis Corporation |
Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
|
MA41346A
(en)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
POST-TRANSCRIPTIONAL REGULATORY ELEMENTS OF MODIFIED HEPATITIS
|
CN107429254B
(en)
|
2015-01-30 |
2021-10-15 |
加利福尼亚大学董事会 |
Protein delivery in primary hematopoietic cells
|
US20170151281A1
(en)
*
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
BR112017018770A2
(en)
|
2015-03-02 |
2018-04-17 |
Innovative Cellular Therapeutics CO., LTD. |
reduced immune tolerance induced by pd-l1
|
AU2016243043B2
(en)
*
|
2015-04-02 |
2021-12-09 |
Memorial Sloan Kettering Cancer Center |
TNFRSF14/ HVEM proteins and methods of use thereof
|
US10471098B2
(en)
|
2015-04-15 |
2019-11-12 |
Prospect Chartercare Rwmc, Llc |
Hepatic arterial infusion of CAR-T cells
|
EP3288568A4
(en)
*
|
2015-04-30 |
2019-01-02 |
University of Southern California |
Secretory tnt car cell immunotherapy
|
EP3466967A1
(en)
|
2015-05-18 |
2019-04-10 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
US20180140691A1
(en)
*
|
2015-05-20 |
2018-05-24 |
Sumitomo Dainippon Pharma Co., Ltd. |
Combination use of wt1 antigen peptide and immunomodulator
|
TWI806815B
(en)
|
2015-05-20 |
2023-07-01 |
美商博德研究所有限公司 |
Shared gata3-related tumor-specific neoantigens
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
CN108337890B
(en)
*
|
2015-06-23 |
2021-10-15 |
纪念斯隆-凯特琳癌症中心 |
Novel PD-1 immunomodulators
|
JP2018518972A
(en)
*
|
2015-06-26 |
2018-07-19 |
ユニバーシティ オブ サザン カリフォルニア |
Masking chimeric antigen receptor T cells for tumor specific activation
|
CN108472314A
(en)
|
2015-07-31 |
2018-08-31 |
明尼苏达大学董事会 |
The cell and therapy of modification
|
CN105111314B
(en)
*
|
2015-08-13 |
2019-01-08 |
成都百世博生物技术有限公司 |
A kind of new fusion protein, pharmaceutical composition and its preparation method and application
|
AR106184A1
(en)
|
2015-09-29 |
2017-12-20 |
Celgene Corp |
PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
|
RU2022102624A
(en)
|
2015-10-01 |
2022-03-10 |
Хит Байолоджикс, Инк. |
COMPOSITIONS AND METHODS FOR CONNECTING TYPE I AND TYPE II EXTRACELLULAR DOMAIN AS HETEROLOGOUS CHIMERIC PROTEINS
|
CN106350533B
(en)
*
|
2015-10-09 |
2020-07-17 |
上海宇研生物技术有限公司 |
Anti-PD-L1-CAR-T and preparation method and application thereof
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
CN105331585A
(en)
*
|
2015-11-13 |
2016-02-17 |
科济生物医药(上海)有限公司 |
Chimeric antigen receptor-modified immunologic effector cell with PD-L1 blocking agent
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
US10533157B1
(en)
*
|
2015-12-03 |
2020-01-14 |
Nantbio, Inc. |
Recombinant NK cells expressing co-stimulatory molecules
|
IL259747B
(en)
|
2015-12-04 |
2022-09-01 |
Memorial Sloan Kettering Cancer Center |
Antibodies targeting fc receptor-like 5 and methods of use
|
WO2017133175A1
(en)
*
|
2016-02-04 |
2017-08-10 |
Nanjing Legend Biotech Co., Ltd. |
Engineered mammalian cells for cancer therapy
|
CN116082505A
(en)
*
|
2016-02-25 |
2023-05-09 |
细胞医学公司 |
Binding members for PD-L1
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
JP7033549B2
(en)
|
2016-05-04 |
2022-03-10 |
フレッド ハッチンソン キャンサー リサーチ センター |
Cell-based neoantigen vaccine and its use
|
CN105950561A
(en)
*
|
2016-05-26 |
2016-09-21 |
江苏杰晟生物科技有限公司 |
Products and preparation method of double chimeric antigen receptor gene modified T lymphocyte targeting breast cancer stem cells
|
MX2018014991A
(en)
|
2016-06-03 |
2019-08-29 |
Memorial Sloan Kettering Cancer Center |
Adoptive cell therapies as early treatment options.
|
WO2017213979A1
(en)
*
|
2016-06-06 |
2017-12-14 |
St. Jude Children's Research Hospital |
Anti-cd7 chimeric antigen receptor and method of use thereof
|
CN107523549A
(en)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
A kind of CAR T cells of high efficiency stable expression activated form antibody and application thereof
|
CN107523547A
(en)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
A kind of CAR T cells of high efficiency stable expression inhibiting antibody and application thereof
|
CN107523545A
(en)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
A kind of lethal cell of high efficiency stable expression antibody and application thereof
|
AU2017301880C1
(en)
|
2016-07-29 |
2022-04-21 |
Juno Therapeutics, Inc. |
Immunomodulatory polypeptides and related compositions and methods
|
JP7062640B2
(en)
*
|
2016-07-29 |
2022-05-06 |
ジュノー セラピューティクス インコーポレイテッド |
Anti-idiotype antibody against anti-CD19 antibody
|
CN109715668A
(en)
|
2016-08-02 |
2019-05-03 |
T细胞受体治疗公司 |
For using fusion protein to carry out the composition and method of TCR reprogramming
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
EP3515944A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
Methods of treating immune disorders using pd-1 binding proteins
|
CN110087657A
(en)
|
2016-09-28 |
2019-08-02 |
阿托莎遗传股份有限公司 |
The method of adoptive cellular treatment
|
CN110139873A
(en)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
HPV specific binding molecules
|
PT3445787T
(en)
|
2016-10-07 |
2021-03-15 |
Tcr2 Therapeutics Inc |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
CN107964549B
(en)
*
|
2016-10-20 |
2020-12-08 |
上海恒润达生生物科技有限公司 |
Chimeric antigen receptor targeting CD22 and uses thereof
|
EP3532078A4
(en)
*
|
2016-10-31 |
2020-06-03 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Artificial antigen presenting cells for expanding immune cells for immunotherapy
|
KR20190085528A
(en)
|
2016-11-22 |
2019-07-18 |
싱가포르국립대학교 |
Blocking chimeric antigen receptors and CD7 expression for immunotherapy of T-cell malignancies
|
CN110177803A
(en)
|
2016-11-22 |
2019-08-27 |
T细胞受体治疗公司 |
For using fusion protein to carry out the composition and method that TCR is reprogramed
|
CN110249046A
(en)
|
2016-12-05 |
2019-09-17 |
朱诺治疗学股份有限公司 |
The generation of engineering cell for adoptive cellular therapy
|
CA3048211A1
(en)
|
2016-12-23 |
2018-06-28 |
Macrogenics, Inc. |
Adam9-binding molecules, and methods of use thereof
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
CN108395478A
(en)
*
|
2017-02-04 |
2018-08-14 |
上海恒润达生生物科技有限公司 |
Target the Chimeric antigen receptor of BCMA and the method and application thereof to its dual modification
|
SI3580561T1
(en)
|
2017-02-12 |
2024-04-30 |
Biontech Us Inc. |
Hla-based methods and compositions and uses thereof
|
CN110300603B
(en)
*
|
2017-02-14 |
2023-04-14 |
亘喜生物科技(上海)有限公司 |
CD47-CAR-T cells
|
CN108424461B
(en)
*
|
2017-02-14 |
2023-03-31 |
亘喜生物科技(上海)有限公司 |
CD47-CAR-T cells
|
EP4269594A3
(en)
|
2017-02-17 |
2023-12-20 |
Fred Hutchinson Cancer Center |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
EP3585425A4
(en)
|
2017-02-27 |
2020-10-28 |
Shattuck Labs, Inc. |
Methods of making and using extracellular domain-based chimeric proteins
|
AU2018224852A1
(en)
|
2017-02-27 |
2019-07-11 |
Shattuck Labs, Inc. |
VSIG8-based chimeric proteins
|
JP7121029B2
(en)
|
2017-02-27 |
2022-08-17 |
シャタック ラボ,インコーポレイテッド |
CSF1R-based chimeric protein
|
CA3056439A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
|
WO2018182511A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
CN107082812B
(en)
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
It is a kind of restore debilitating immune cell function fusion protein and its application
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
WO2018191553A1
(en)
|
2017-04-12 |
2018-10-18 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
MX2019012398A
(en)
|
2017-04-18 |
2020-09-25 |
Broad Inst Inc |
Compositions for detecting secretion and methods of use.
|
EP3612222A4
(en)
*
|
2017-04-19 |
2020-12-23 |
University of Southern California |
Compositions and methods for treating cancer
|
CA3059755A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
|
CN108864286B
(en)
*
|
2017-05-16 |
2023-08-29 |
上海恒润达生生物科技股份有限公司 |
Chimeric antigen receptor targeting CD19, method for combined expression of anti-PD 1 antibody variable region and application thereof
|
WO2018213467A1
(en)
|
2017-05-16 |
2018-11-22 |
The Johns Hopkins University |
Manabodies and methods of using
|
CA3064000A1
(en)
|
2017-05-24 |
2018-11-29 |
Effector Therapeutics, Inc. |
Methods and compositions for cellular immunotherapy
|
CN107164410B
(en)
*
|
2017-05-27 |
2019-09-03 |
上海优卡迪生物医药科技有限公司 |
It is a kind of based on the prostate cancer CAR-T therapy vector and its construction method of OCTS technology and application
|
CN107245500B
(en)
*
|
2017-05-27 |
2019-05-17 |
上海优卡迪生物医药科技有限公司 |
A kind of leaching based on OCTS technology is leukaemia CAR-T therapy vector and its construction method and application
|
CN107325185B
(en)
*
|
2017-06-06 |
2019-09-20 |
上海优卡迪生物医药科技有限公司 |
The bis- targeting Chimeric antigen receptors of anti-PSCA and PDL1, encoding gene and expression vector based on OCTS-CAR
|
CN107337736B
(en)
*
|
2017-06-06 |
2019-07-26 |
上海优卡迪生物医药科技有限公司 |
The bis- targeting Chimeric antigen receptors of OCTS-CAR, encoding gene, recombinant expression carrier and its building and application
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
Adeno-associated viral vectors for gene therapy
|
AU2018301393A1
(en)
|
2017-07-11 |
2020-02-06 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
CN107245106B
(en)
*
|
2017-07-18 |
2020-06-12 |
深圳市免疫基因治疗研究院 |
Chimeric antigen receptor based on CD10 and application thereof
|
CN107337737B
(en)
*
|
2017-07-18 |
2020-02-07 |
深圳市免疫基因治疗研究院 |
Chimeric antigen receptor and application thereof
|
CN107245107B
(en)
*
|
2017-07-18 |
2020-02-07 |
深圳市免疫基因治疗研究院 |
Chimeric antigen receptor based on CD20 and application thereof
|
CN107312098B
(en)
*
|
2017-07-18 |
2020-06-12 |
深圳市免疫基因治疗研究院 |
Chimeric antigen receptor based on CD22 and application thereof
|
CN116832020A
(en)
|
2017-09-11 |
2023-10-03 |
阿托萨治疗学公司 |
Methods of making and using endoxifen
|
CN107557336B
(en)
*
|
2017-09-15 |
2020-02-14 |
山东兴瑞生物科技有限公司 |
Immune cell modified by anti-MUC16 safe chimeric antigen receptor and application thereof
|
CN111511388A
(en)
|
2017-09-21 |
2020-08-07 |
博德研究所 |
Systems, methods, and compositions for targeted nucleic acid editing
|
CN109554349B
(en)
*
|
2017-09-27 |
2022-06-24 |
亘喜生物科技(上海)有限公司 |
Engineered immune cells with silenced PD-1 gene expression
|
CN109554348A
(en)
*
|
2017-09-27 |
2019-04-02 |
亘喜生物科技(上海)有限公司 |
It can induce the engineering immunocyte of secretion anti-cd 47 antibody
|
US20190194340A1
(en)
|
2017-09-29 |
2019-06-27 |
Cell Design Labs, Inc. |
Methods of making bispecific anti-cd307e and anti-bcma chimeric antigen receptors and uses of the same
|
CN109593721B
(en)
*
|
2017-09-30 |
2022-11-01 |
亘喜生物科技(上海)有限公司 |
Engineered immune cells targeting human mesothelin with suicide gene switch
|
WO2019070541A1
(en)
|
2017-10-03 |
2019-04-11 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
EP3697435A1
(en)
|
2017-10-20 |
2020-08-26 |
Fred Hutchinson Cancer Research Center |
Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
|
US11732257B2
(en)
|
2017-10-23 |
2023-08-22 |
Massachusetts Institute Of Technology |
Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
EP3703688A2
(en)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
WO2019090003A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
WO2019096136A1
(en)
*
|
2017-11-14 |
2019-05-23 |
拜西欧斯(北京)生物技术有限公司 |
Anti-pd-1 antibody, preparation method therefor and use thereof
|
AU2018367452A1
(en)
*
|
2017-11-14 |
2020-06-11 |
Memorial Sloan-Kettering Cancer Center |
IL-36 secreting immunoresponsive cells and uses thereof
|
US11649294B2
(en)
*
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
TW201930340A
(en)
|
2017-12-18 |
2019-08-01 |
美商尼恩醫療公司 |
Neoantigens and uses thereof
|
CN109971721B
(en)
*
|
2017-12-28 |
2023-10-31 |
上海细胞治疗研究院 |
Interval Pi Sute-specific CAR-T cells from CD 47-expressing antibodies and uses thereof
|
CN109971722B
(en)
*
|
2017-12-28 |
2023-09-01 |
上海细胞治疗研究院 |
CD 19-targeted and high-level stable CD40 antibody-expressing CAR-T cells and uses thereof
|
CN109971716B
(en)
*
|
2017-12-28 |
2023-08-01 |
上海细胞治疗研究院 |
EGFR-specific CAR-T cells from autocrine CD47 antibodies and uses thereof
|
CN109971725B
(en)
*
|
2017-12-28 |
2024-02-02 |
上海细胞治疗研究院 |
Antibody-modified chimeric antigen receptor-modified T cells and uses thereof
|
JP7416695B2
(en)
*
|
2017-12-29 |
2024-01-17 |
メモリアル スローン-ケタリング キャンサー センター |
Enhanced chimeric antigen receptors and their uses
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
WO2019136305A1
(en)
*
|
2018-01-04 |
2019-07-11 |
Neumedicines Inc. |
Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer
|
AU2019206724A1
(en)
*
|
2018-01-15 |
2020-07-16 |
Kite Pharma, Inc. |
Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1BB agonist
|
EP3768700A1
(en)
|
2018-03-23 |
2021-01-27 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
WO2019186274A2
(en)
|
2018-03-30 |
2019-10-03 |
University Of Geneva |
Micro rna expression constructs and uses thereof
|
MX2020010460A
(en)
|
2018-04-05 |
2021-01-29 |
Juno Therapeutics Inc |
T cell receptors and engineered cells expressing same.
|
CA3094468A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
CN112368013A
(en)
*
|
2018-04-26 |
2021-02-12 |
贝勒医学院 |
Auto/allogeneic immune defense receptors for selectively targeting activated pathogenic T cells and NK cells
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
CN112203725A
(en)
|
2018-06-13 |
2021-01-08 |
诺华股份有限公司 |
BCMA chimeric antigen receptors and uses thereof
|
SG11202011751WA
(en)
|
2018-06-22 |
2021-01-28 |
Kite Pharma Inc |
Chimeric transmembrane proteins and uses thereof
|
CA3109630A1
(en)
*
|
2018-08-16 |
2020-02-20 |
Memorial Sloan-Kettering Cancer Center |
Leucine zipper-based compositions and methods of use
|
US20210355522A1
(en)
|
2018-08-20 |
2021-11-18 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease activity and uses thereof
|
US20210324357A1
(en)
|
2018-08-20 |
2021-10-21 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
WO2020068304A2
(en)
|
2018-08-20 |
2020-04-02 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
US10780121B2
(en)
|
2018-08-29 |
2020-09-22 |
Shattuck Labs, Inc. |
FLT3L-based chimeric proteins
|
CA3114788A1
(en)
*
|
2018-09-28 |
2020-04-02 |
Memorial Sloan-Kettering Cancer Center |
Immunoresponsive cells expressing dominant negative fas and uses thereof
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
WO2020092057A1
(en)
|
2018-10-30 |
2020-05-07 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
BR112021008263A2
(en)
*
|
2018-10-31 |
2021-08-10 |
Humanigen, Inc. |
materials and methods for cancer treatment
|
EP3877053A1
(en)
|
2018-11-05 |
2021-09-15 |
Ludwig Institute for Cancer Research Ltd |
Humanized and variant tgf-beta3 specific antibodies and methods and uses thereof
|
CA3118186A1
(en)
|
2018-11-05 |
2020-05-14 |
Ludwig Institute For Cancer Research Ltd |
Humanized and variant tgf-.beta.1 specific antibodies and methods and uses thereof
|
CN113166269A
(en)
|
2018-11-13 |
2021-07-23 |
指南针制药有限责任公司 |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
US20210393692A1
(en)
*
|
2018-11-13 |
2021-12-23 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for adoptive cell therapy for cancer
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
CN113474840A
(en)
|
2018-12-21 |
2021-10-01 |
百欧恩泰美国公司 |
Methods and systems for predicting HLA class II specific epitopes and characterizing CD4+ T cells
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
WO2020180882A1
(en)
|
2019-03-05 |
2020-09-10 |
Nkarta, Inc. |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
EP3952913A4
(en)
*
|
2019-04-12 |
2023-05-10 |
The Johns Hopkins University |
Tolerogenic artificial antigen-presenting cells
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
CN110343667A
(en)
*
|
2019-07-17 |
2019-10-18 |
贝赛尔特(北京)生物技术有限公司 |
Immunocyte of engineering and its preparation method and application
|
WO2021026155A1
(en)
*
|
2019-08-05 |
2021-02-11 |
Nantkwest, Inc. |
Artificial target cells for in-vitro car cytotoxicity and adcc validation
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
MX2022002747A
(en)
|
2019-09-10 |
2022-04-06 |
Obsidian Therapeutics Inc |
Ca2-il15 fusion proteins for tunable regulation.
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
WO2021092019A1
(en)
*
|
2019-11-04 |
2021-05-14 |
Inovio Pharmaceuticals, Inc. |
Combination therapy to treat brain cancer
|
CN112079934B
(en)
*
|
2019-12-17 |
2021-01-29 |
合源生物科技(天津)有限公司 |
Chimeric antigen receptor targeting CD19 and application thereof
|
CA3188988A1
(en)
|
2020-08-13 |
2022-02-17 |
Sidi CHEN |
Compositions and methods for engineering and selection of car t cells with desired phenotypes
|
WO2022036495A1
(en)
|
2020-08-17 |
2022-02-24 |
Utc Therapeutics Inc. |
Lymphocytes-antigen presenting cells co-stimulators and uses thereof
|
US20230322899A1
(en)
*
|
2020-08-28 |
2023-10-12 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Fusion protein enhancing cell therapy
|
CN111925990B
(en)
*
|
2020-09-02 |
2022-08-26 |
北京立康生命科技有限公司 |
Anti-MUC16 CAR-T cell aiming at ovarian cancer and preparation method thereof
|
IL302412A
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
WO2022109611A1
(en)
|
2020-11-20 |
2022-05-27 |
Simcere Innovation, Inc. |
Armed dual car-t compositions and methods for cancer immunotherapy
|
AU2022257812A1
(en)
*
|
2021-04-12 |
2023-10-12 |
Medgene Therapeutics, Inc. |
Method for activating and proliferating cd8 t cells exposed to antigen, cd8 t cells, prepared thereby, having enhanced anticancer activity, and use thereof
|
WO2022235832A1
(en)
|
2021-05-06 |
2022-11-10 |
Ludwig Institute For Cancer Research Ltd |
Compositions and methods for immunotherapy
|
AU2022271801A1
(en)
*
|
2021-05-13 |
2023-11-09 |
Memorial Sloan Kettering Cancer Center |
Nkg2c+ t cells and methods of use thereof
|
WO2023173137A1
(en)
|
2022-03-11 |
2023-09-14 |
Yale University |
Compositions and methods for efficient and stable genetic modification of eukaryotic cells
|
WO2023220644A1
(en)
|
2022-05-10 |
2023-11-16 |
Yale University |
Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
|
WO2023243890A1
(en)
*
|
2022-06-15 |
2023-12-21 |
주식회사 셀리드 |
Vaccine comprising natural killer cells loaded with ligands of natural killer t cells and cancer antigens
|
WO2023246840A1
(en)
*
|
2022-06-22 |
2023-12-28 |
Wuhan Houxian Biopharmaceutical Co. Ltd. |
Combination of il-12 and ox40l for cancer immunotherapy
|
WO2024064824A2
(en)
|
2022-09-21 |
2024-03-28 |
Yale University |
Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
CN115850519B
(en)
*
|
2022-12-12 |
2023-06-23 |
南京市浦口医院 |
Chimeric antigen receptor targeting MAGE-A1 and capable of autocrine CD47scFv and application thereof
|